Durham-based drug discovery company SCYNEXIS, Inc., (www.scynexis.com) secured $13.5 million in Series C-2 financing. The funding was led by Merial Limited and sanofi-aventis. SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund, also participated. SCYNEXIS is a spin-off created by a team of researchers from the Triangle’s Aventis CropScience and is the primary research partner for animal health company Merial.
SCYNEXIS, Inc. is a CED member.